257 related articles for article (PubMed ID: 26801900)
1. Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
Cocca M; Bedognetti D; La Bianca M; Gasparini P; Girotto G
J Transl Med; 2016 Jan; 14():22. PubMed ID: 26801900
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women.
Jabir FA; Hoidy WH
Clin Breast Cancer; 2018 Oct; 18(5):e863-e868. PubMed ID: 29482947
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
4. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
[TBL] [Abstract][Full Text] [Related]
5. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the 1758G>C and 2880A>G variants within the NCOA3 gene in a breast cancer affected Australian population.
Gabrovska PN; Smith RA; O'Leary G; Haupt LM; Griffiths LR
Gene; 2011 Aug; 482(1-2):68-72. PubMed ID: 21601620
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
8. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics and breast cancer.
Lymberis SC; Parhar PK; Katsoulakis E; Formenti SC
Pharmacogenomics; 2004 Jan; 5(1):31-55. PubMed ID: 14683419
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Awada Z; Haider S; Tfayli A; Bazarbachi A; El-Saghir NS; Salem Z; Shamseddine A; Taher A; Zgheib NK
OMICS; 2013 Jul; 17(7):353-67. PubMed ID: 23758476
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
Iyer PM; Karthikeyan S; Sanjay Kumar P; Krishnan Namboori PK
Funct Integr Genomics; 2017 Jul; 17(4):375-385. PubMed ID: 28470340
[TBL] [Abstract][Full Text] [Related]
13. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; McCredie MR; Giles GG; Venter DJ; Southey MC; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):439-43. PubMed ID: 12010857
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.
Zhai X; Gao J; Hu Z; Tang J; Qin J; Wang S; Wang X; Jin G; Liu J; Chen W; Chen F; Wang X; Wei Q; Shen H
BMC Cancer; 2006 May; 6():138. PubMed ID: 16723031
[TBL] [Abstract][Full Text] [Related]
15. Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients.
Tulsyan S; Agarwal G; Lal P; Mittal B
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1065-78. PubMed ID: 25223935
[TBL] [Abstract][Full Text] [Related]
16. Mortality from skin melanoma in Italy and Friuli-Venezia Giulia region, 1970-1989.
Franceschi S; Bidoli E; Prati S; Fascioli S; La Vecchia C
Tumori; 1994 Aug; 80(4):251-6. PubMed ID: 7974794
[TBL] [Abstract][Full Text] [Related]
17. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.
Jamieson D; Cresti N; Bray J; Sludden J; Griffin MJ; Hawsawi NM; Famie E; Mould EV; Verrill MW; May FE; Boddy AV
Pharmacogenet Genomics; 2011 Dec; 21(12):808-19. PubMed ID: 21946896
[TBL] [Abstract][Full Text] [Related]
18. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
19. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients.
Karakus N; Kara N; Ulusoy AN; Ozaslan C; Bek Y
DNA Cell Biol; 2011 Jun; 30(6):371-7. PubMed ID: 21323572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
